343 related articles for article (PubMed ID: 34313532)
1. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
3. Toward Drug-Like Multispecific Antibodies by Design.
Sawant MS; Streu CN; Wu L; Tessier PM
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
[TBL] [Abstract][Full Text] [Related]
4. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
[TBL] [Abstract][Full Text] [Related]
5. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.
Zhang Y; Wu L; Gupta P; Desai AA; Smith MD; Rabia LA; Ludwig SD; Tessier PM
Mol Pharm; 2020 Jul; 17(7):2555-2569. PubMed ID: 32453957
[TBL] [Abstract][Full Text] [Related]
7. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.
Tomar DS; Li L; Broulidakis MP; Luksha NG; Burns CT; Singh SK; Kumar S
MAbs; 2017 Apr; 9(3):476-489. PubMed ID: 28125318
[TBL] [Abstract][Full Text] [Related]
8. Improving antibody drug development using bionanotechnology.
Makowski EK; Schardt JS; Tessier PM
Curr Opin Biotechnol; 2022 Apr; 74():137-145. PubMed ID: 34890875
[TBL] [Abstract][Full Text] [Related]
9. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
10. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.
Tessier PM; Wu J; Dickinson CD
Expert Opin Drug Deliv; 2014 Apr; 11(4):461-5. PubMed ID: 24444112
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
12. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
14. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
Lavoisier A; Schlaeppi JM
MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
[TBL] [Abstract][Full Text] [Related]
15. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
[TBL] [Abstract][Full Text] [Related]
16. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.
Sule SV; Dickinson CD; Lu J; Chow CK; Tessier PM
Mol Pharm; 2013 Apr; 10(4):1322-31. PubMed ID: 23383873
[TBL] [Abstract][Full Text] [Related]
17. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
18. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
19. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
20. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
